<![CDATA[Teclistamab Combos Improve PFS, OS in Relapsed/Refractory Multiple Myeloma]]>

Phase 3positiveTeclistamabPositive

AI Analysis

Summary

Phase 3 MonumenTAL-6 trial data demonstrates that teclistamab combination therapy improves progression-free survival and overall survival in relapsed/refractory multiple myeloma by simultaneously targeting BCMA and GPRC5D.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Teclistamab combination improved PFS and OS in relapsed/refractory multiple myeloma

Importance:7/10

Sentiment:

0.75

multiple myelomaBCMAGPRC5DPhase 3MonumenTAL-6PFSOS

Related Companies

$CBDY

Read the original article

Published by Cancer Network on July 23, 2026 3:23 PM

Read Original